Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hyperglycemia and hypoglycemia currently are considered risk factors for cardiovascular disease in type 1diabetes. Both acute hyperglycemia and hypoglycemia induce endothelial dysfunction and inflammation, raising the oxidative stress. Glucagon-like peptide 1 (GLP-1) has antioxidant properties, and evidence suggests that it protects endothelial function. RESEARCH DESIGN AND METHODS: The effect of both acute hyperglycemia and acute hypoglycemia in type 1 diabetes, with or without the simultaneous infusion of GLP-1, on oxidative stress (plasma nitrotyrosine and plasma 8-iso prostaglandin F2alpha), inflammation (soluble intercellular adhesion molecule-1 and interleukin-6), and endothelial dysfunction has been evaluated. RESULTS: Both hyperglycemia and hypoglycemia acutely induced oxidative stress, inflammation, and endothelial dysfunction. GLP-1 significantly counterbalanced these effects. CONCLUSIONS: These results suggest a protective effect of GLP-1 during both hypoglycemia and hyperglycemia in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of T2DM, GLP-1RAs have produced a range of beneficial pancreatic impacts, leading to significant enhancements in glycated hemoglobin (HbA1c), fasting and postprandial plasma glucose levels, and pancreatic beta-cell performance indicators.72–74”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In people with T1D, GLP-1 infusion counteracted hypo- and hyperglycemia-induced increases in the inflammation markers IL-6 and soluble intercellular adhesion molecule-1 (sICAM-1) (45).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The Value of Cardiovascular Autonomic Function Tests: 10 Years Experience in Diabetes
Ewing, D. J., Martyn, C. N., Young, R. J., & Clarke, B. F. (1985) · Diabetes Care · doi:10.2337/diacare.8.5.491 · Cited by 1,434
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress
Mercuri, F., Tonutti, L., Taboga, C., Ceriello, A., Assaloni, R., Motz, E., & Quagliaro, L. (2001) · Diabetologia · doi:10.1007/s001250100529 · Cited by 419
Self-citationVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 2×
“Recent evidence suggests that hypoglycemia also may play an important role in favoring diabetic vascular complications (1).”
BackgroundAmiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Burgos-Morón, E., Abad-Jiménez, Z., Martínez de Marañón, A., Iannantuoni, F., Escribano-López, I., López-Domènech, S., Salom, C., Jover, A., Mora, V., Roldan, I., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091385 · Cited by 581
Papachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Regulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Inflammageing and metaflammation: The yin and yang of type 2 diabetes
Prattichizzo, F., De Nigris, V., Spiga, R., Mancuso, E., La Sala, L., Antonicelli, R., Testa, R., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.10.003 · Cited by 249
Self-citationEffects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling
Oh, Y., & Jun, H.-S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010026 · Cited by 217
“4 pmol/kg/min) for 2 h reduced 8-iso-prostaglandin F2α (8-iso-PGF2α) and nitrotyrosine (oxidative stress markers) in plasma during a hypoglycemia or hyperglycemia clamp in both type 1 and type 2 diabetic patients [108,109].”
BackgroundCOVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course
Landstra, C. P., & de Koning, E. J. P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.649525 · Cited by 206
Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?
Saisho, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151018381 · Cited by 195
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 191
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control
Scheen, A. J., Esser, N., & Paquot, N. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.003 · Cited by 171
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151
“36 37 SGLT-2 inhibitors, on the other hand, exert their antihyperglycemic effects by inhibiting the reabsorption of glucose in the proximal tubules of the kidneys, resulting in urinary glucose excretion.”
BackgroundGlycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
Self-citationWei, R., Ma, S., Wang, C., Ke, J., Yang, J., Li, W., Liu, Y., Hou, W., Feng, X., Wang, G., et al. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00400.2015 · Cited by 137
“GLP-1 and its analogs downregulate adhesion molecules and nuclear factor- B or activator protein-1 signaling, which are the major redox-sensitive transcriptional pathways responsible for proinflammatory cytokine expression in human vascular endothelial cells and in animal models and diabetic patients (12, 16, 24, 25).”
BackgroundIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Glucose Variability: How Does It Work?
Klimontov, V. V., Saik, O., & Korbut, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157783 · Cited by 142
Chen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 123
Rizzo, M. R., Barbieri, M., Boccardi, V., Angellotti, E., Marfella, R., & Paolisso, G. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu032 · Cited by 105
Type 1 diabetes and cardiovascular disease
Schnell, O., Cappuccio, F. P., Genovese, S., Standl, E., Valensi, P. E., & Ceriello, A. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-156 · Cited by 126
Self-citationDiabetes and COVID-19: The past, the present, and the future
Pranata, R., Henrina, J., Raffaello, W. M., Lawrensia, S., & Huang, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154814 · Cited by 121
Chen, W. R., Chen, Y. D., Tian, F., Yang, N., Cheng, L. Q., Hu, S. Y., Wang, J., Yang, J. J., Wang, S. F., & Gu, X. F. (2016) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.116.005146 · Cited by 100
Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 144
Perspectives in GLP-1 Research: New Targets, New Receptors
Cantini, G., Mannucci, E., & Luconi, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.03.017 · Cited by 102
Chen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 89
Ceriello, A., Novials, A., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Testa, R., Bucciarelli, L., Rondinelli, M., & Genovese, S. (2014) · Diabetes Care · doi:10.2337/dc13-2618 · Cited by 78
Self-citationSong, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Self-citationPerkins, J. M., Joy, N. G., Tate, D. B., & Davis, S. N. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2015 · Cited by 80
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
“The figure illustrates GLP-1(7-36) amide.”
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
Sajja, R. K., Green, K. N., & Cucullo, L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122358 · Cited by 69
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
Lg, S., Дігтяр, Н. І., Селіхова, Л. Г., Кайдашева, Е. І., Shlykova, O. A., Vesnina, L. E., & Кайдашев, І. П. (2019) · Romanian Journal of Internal Medicine · doi:10.2478/rjim-2019-0003 · Cited by 81
GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65
“The glucoregulatory benefits of glucagon-like 355 peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical 356 patients: a pilot study.”
BackgroundBajaj, H. S., Venn, K., Ye, C., Patrick, A., Kalra, S., Khandwala, H., Aslam, N., Twum-Barima, D., & Aronson, R. (2017) · Diabetes Care · doi:10.2337/dc16-1582 · Cited by 65
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Bucciarelli, L., Rondinelli, M., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc13-0750 · Cited by 65
Self-citationVascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance
Pujadas, G., & Drucker, D. J. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1078 · Cited by 65
Self-citationKuroki, T., Tanaka, R., Shimada, Y., Yamashiro, K., Ueno, Y., Shimura, H., Urabe, T., & Hattori, N. (2016) · Stroke · doi:10.1161/strokeaha.116.012934 · Cited by 60
Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020775 · Cited by 61
Self-citationRelationship between diabetes and respiratory diseases—Clinical and therapeutic aspects
Visca, D., Pignatti, P., Spanevello, A., Lucini, E., & Rocca, E. L. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.008 · Cited by 68
Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
Roan, J.-N., Cheng, H.-N., Young, C., Lee, C.-J., Yeh, M.-L., Luo, C.-Y., Tsai, Y., & Lam, C. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2016.09.024 · Cited by 57
Thomas, M. C., Coughlan, M. T., & Cooper, M. E. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.01.004 · Cited by 56
Saad, M. I., Abdelkhalek, T. M., Saleh, M. M., Kamel, M. A. E.-N., Youssef, M., Tawfik, S. H., & Domínguez, H. (2015) · Endocrine · doi:10.1007/s12020-015-0709-4 · Cited by 67
Shinjo, T., Nakatsu, Y., Iwashita, M., Sano, T., Sakoda, H., Ishihara, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Tsuchiya, Y., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00553.2014 · Cited by 59
Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease
Kavurma, M. M., Bursill, C. A., Stanley, C. P., Passam, F. H., Cartland, S. P., Patel, S., Loa, J., Figtree, G. A., Golledge, J., Aitken, S., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1054576 · Cited by 69
Diabetes pathogenesis and management: the endothelium comes of age
Love, K. M., Barrett, E. J., Malin, S. K., Reusch, J. E. B., Regensteiner, J. G., & Liu, Z. (2021) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjab024 · Cited by 57
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
Postprandial Inflammation: Targeting Glucose and Lipids
de Vries, M. A., Klop, B., Janssen, H. W., Njo, T. L., Westerman, E. M., & Cabezas, M. C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-07320-0_12 · Cited by 57
Ohara, M., Nagaike, H., Goto, S., Fukase, A., Tanabe, Y., Tomoyasu, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.02.017 · Cited by 59
Hakon, J., Ruscher, K., Romner, B., & Tomasevic, G. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120074 · Cited by 52
Chen, W. R., Tian, F., Chen, Y. D., Wang, J., Yang, J. J., Wang, Z. F., Wang, J. D., & Ning, Q. X. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.12.009 · Cited by 49
Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?
Snaith, J. R., Holmes-Walker, D. J., & Greenfield, J. R. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.11.007 · Cited by 45
João, A. L., Reis, F., & Fernandes, R. (2016) · Obesity Reviews · doi:10.1111/obr.12421 · Cited by 44
Lin, C.-H., & LIN, C.-C. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3255 · Cited by 45
The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology
Yang, S., Park, K., & Zhou, Y.-J. (2015) · Angiology · doi:10.1177/0003319715623400 · Cited by 55
Saik, O., & Klimontov, V. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228691 · Cited by 48
Savarese, G., Butler, J., Lund, L. H., Bhatt, D. L., & Anker, S. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab271 · Cited by 48
Vergès, B. L., & Charbonnel, B. H. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30067-8 · Cited by 44
COVID-19: Diabetes Perspective—Pathophysiology and Management
Dallavalasa, S., Tulimilli, S. V., Janhavi, P., Ramachandra, R., Madhunapantula, S. V., & Veeranna, R. P. (2023) · Pathogens · doi:10.3390/pathogens12020184 · Cited by 47
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Luo, M., Zheng, Y., Tang, S., Gu, L., Zhu, Y., Ying, R., Liu, Y., Ma, J., Guo, R., Gao, P., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1166178 · Cited by 45
Joy, N. G., Perkins, J. M., Mikeladze, M., Younk, L., Tate, D. B., & Davis, S. N. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.06.030 · Cited by 33
Pendharkar, S. A., Singh, R. G., Chand, S. K., Cervantes, A., & Petrov, M. S. (2017) · Inflammation Research · doi:10.1007/s00011-017-1125-4 · Cited by 43
Al‐Qaissi, A., Papageorgiou, M., Deshmukh, H., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13548 · Cited by 38
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Impaired Vascular Redox Signaling in the Vascular Complications of Obesity and Diabetes Mellitus
Akoumianakis, I., & Antoniades, C. A. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7421 · Cited by 41
Brenner, C., Kränkel, N., Kühlenthal, S., Israel, L., Remm, F., Fischer, C., Herbach, N., Speer, T., Grabmaier, U., Laskowski, A., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.016 · Cited by 39
Ravassa, S., Beaumont, J., Huerta, A., Barba, J., Coma-Canella, I., González, A., López, B., & Díez, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.01.002 · Cited by 34
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
MicroRNA-200a improves diabetic endothelial dysfunction by targeting KEAP1/NRF2
Jiang, Z., Wu, J., Ma, F., Jiang, J., Xu, L., Du, L., Huang, W., Wang, Z., Jia, Y., Lu, L., et al. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0414 · Cited by 34
Le, T. D., Nguyen, N. P. T., Tran, T. T. H., Cong, T. L., Nguyen, L. H. T., Nhu, B. D., Nguyen, S. T., Ngo, M. V., Dinh, T. H., Nguyen, H. T., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s344532 · Cited by 41
Pignatelli, P., Baratta, F., Buzzetti, R., D’Amico, A., Castellani, V., Bartimoccia, S., Siena, A., D’Onofrio, L., Maddaloni, E., Pingitore, A., et al. (2022) · Antioxidants · doi:10.3390/antiox11101878 · Cited by 33
Yaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31
“Vascular endothelial cells have a significant role in the homeostasis of cardiovascular function and BP homeostasis [58, 59].”
BackgroundInfluentialMacrophage polarization regulates the pathogenesis and progression of autoimmune diseases
Wu, S., Zhao, S., Hai, L., Yang, Z., Wang, S., Cui, D., & Xie, J. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103820 · Cited by 38
Petersen, K. E., Rakipovski, G., Raun, K., & Lykkesfeldt, J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666150918150608 · Cited by 37
Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease
Remm, F., Franz, W., & Brenner, C. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv044 · Cited by 31
Lin, L., Chen, Z., Huang, C., Wu, Y., Huang, L., Wang, L., Ke, S., & Liu, L. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03101-0 · Cited by 31
Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy
Avogaro, A., de Kreutzenberg, S. V., & Fadini, G. P. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0483-3 · Cited by 30
Pleiotropic effects of hypoglycemic agents: implications in asthma and COPD
Rogliani, P., Ora, J., Daniele, N. D., & Lauro, D. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.01.002 · Cited by 32
Endothelium as a Therapeutic Target in Diabetes Mellitus: From Basic Mechanisms to Clinical Practice
Tentolouris, A., Eleftheriadou, I., Tzeravini, E., Tsilingiris, D., Paschou, S. Α., Siasos, G., & Tentolouris, N. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190119154152 · Cited by 34
Protein tyrosine nitration in atherosclerotic endothelial dysfunction
Jiang, M., Zhao, X., Jiang, Z., Wang, G., & Zhang, D. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.02.004 · Cited by 35
Tang, J., Pei, Y., & Zhou, G. (2013) · Experimental Gerontology · doi:10.1016/j.exger.2013.04.013 · Cited by 28
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
Gordin, D., & Groop, P. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816636894 · Cited by 31
Li, Y., Huang, C., Fu, W., Zhang, H., Lao, Y., Zhou, H., Tan, H., & Xu, H. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112645 · Cited by 28
Navabi, R., Negahdari, B., Hajizadeh‐Saffar, E., Hajinasrollah, M., Jenab, Y., Rabbani, S., Pakzad, M., Hassani, S., Hezavehei, M., Atrabi, M. J., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119374 · Cited by 27
Nagaike, H., Ohara, M., Kohata, Y., Hiromura, M., Tomoyasu, M., Takada, M., Yamamoto, T., Hayashi, T., Fukui, T., & Hirano, T. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0560-8 · Cited by 26
Polat, Ş. B., Uğurlu, N., Aslan, N., Çuhacı, N., Ersoy, R., & Çakır, B. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000116 · Cited by 25
Therapeutic Interventions to Block Oxidative Stress-Associated Pathologies
Prasad, N., Ramteke, P., Dholia, N., & Yadav, U. C. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805417-8.00027-5 · Cited by 32
Klimontov, V. V., Mavlianova, K. R., Орлов, Н. Б., Semenova, J. F., & Korbut, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11102843 · Cited by 28
The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
Mustafa, O. G., & Whyte, M. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3191 · Cited by 27
Zhang, G., Kim, S., Gu, X., Yu, S. P., & Wei, L. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00446-w · Cited by 28
Antioxidative Potentials of Incretin‐Based Medications: A Review of Molecular Mechanisms
Yaribeygi, H., Maleki, M., Sathyapalan, T., Jamialahmadi, T., & Sahebkar, A. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9959320 · Cited by 26
Battini, V., van Manen, R. P., Gringeri, M., Mosini, G., Guarnieri, G., Bombelli, A., Pozzi, M., Nobile, M., Radice, S., Clementi, E., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1128387 · Cited by 27
Li, F., Chen, J., Leng, F., Lu, Z., & Ling, Y. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-124421 · Cited by 25
Metadata
- Authors
- Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S.
- Affiliations
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Diabetes and Endocrinology, Insititut d'Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Hospital Clínic Barcelona, Barcelona, Spain
- University of Campania "Luigi Vanvitelli" (IT)
- MultiMedica (IT)
- Corresponding author
- Ceriello, Antonio
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-11
- Volume
- 36
- Issue
- 8
- Pages
- 2346-2350
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3714509
- OpenAlex
- W2148254941
- Cited by
- 204
- References
- 28
- Citations by year
- 2026: 16 · 2025: 11 · 2024: 16 · 2023: 19 · 2022: 16 · 2021: 23 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 9 · 2016: 22 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, type 1 diabetes, hyperglycemia, hypoglycemia, endothelial dysfunction, oxidative stress, inflammation, nitrotyrosine, 8-isoprostane, interleukin-6, soluble intercellular adhesion molecule-1, cardiovascular risk
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Endothelium, Vascular, Female, Humans, Hyperglycemia, Hypoglycemia, Inflammation, Male, Interleukin-6, Oxidative Stress, Intercellular Adhesion Molecule-1, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.